THROMBIN-JMI: payments to doctors
Payments that named THROMBIN-JMI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Pfizer?
Pfizer reported the most payments naming THROMBIN-JMI. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $26K
- Providers
- 668
- Transactions
- 875
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 668 providers the average total is $39, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $24,271 | 93.7% |
| Hospira, Inc. | $1,642 | 6.3% |
Other products from Pfizer
The company that reported the most payments naming THROMBIN-JMI also reports against these.